BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Clinical Outcome
22 results:

  • 1. Patient-Specific Measurable Residual Disease Markers Predict outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
    J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
    Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
    Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of mds with Ring Sideroblasts.
    Todisco G; Creignou M; Bernard E; Björklund AC; Moura PL; Tesi B; Mortera-Blanco T; Sander B; Jansson M; Walldin G; Barbosa I; Reinsbach SE; Hofman IJ; Nilsson C; Yoshizato T; Dimitriou M; Chang D; Olafsdottir S; Venckute Larsson S; Tobiasson M; Malcovati L; Woll P; Jacobsen SEW; Papaemmanuil E; Hellström-Lindberg E
    Clin Cancer Res; 2023 Oct; 29(20):4256-4267. PubMed ID: 37498312
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
    Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
    Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
    Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
    Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
    Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
    Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
    Sauta E; Robin M; Bersanelli M; Travaglino E; Meggendorfer M; Zhao LP; Caballero Berrocal JC; Sala C; Maggioni G; Bernardi M; Di Grazia C; Vago L; Rivoli G; Borin L; D'Amico S; Tentori CA; Ubezio M; Campagna A; Russo A; Mannina D; Lanino L; Chiusolo P; Giaccone L; Voso MT; Riva M; Oliva EN; Zampini M; Riva E; Nibourel O; Bicchieri M; Bolli N; Rambaldi A; Passamonti F; Savevski V; Santoro A; Germing U; Kordasti S; Santini V; Diez-Campelo M; Sanz G; Sole F; Kern W; Platzbecker U; Ades L; Fenaux P; Haferlach T; Castellani G; Della Porta MG
    J Clin Oncol; 2023 May; 41(15):2827-2842. PubMed ID: 36930857
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
    Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
    [No Abstract]    [Full Text] [Related]  

  • 9. clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.
    Sahoo SS; Pastor VB; Goodings C; Voss RK; Kozyra EJ; Szvetnik A; Noellke P; Dworzak M; Starý J; Locatelli F; Masetti R; Schmugge M; De Moerloose B; Catala A; Kállay K; Turkiewicz D; Hasle H; Buechner J; Jahnukainen K; Ussowicz M; Polychronopoulou S; Smith OP; Fabri O; Barzilai S; de Haas V; Baumann I; Schwarz-Furlan S; ; Niewisch MR; Sauer MG; Burkhardt B; Lang P; Bader P; Beier R; Müller I; Albert MH; Meisel R; Schulz A; Cario G; Panda PK; Wehrle J; Hirabayashi S; Derecka M; Durruthy-Durruthy R; Göhring G; Yoshimi-Noellke A; Ku M; Lebrecht D; Erlacher M; Flotho C; Strahm B; Niemeyer CM; Wlodarski MW
    Nat Med; 2021 Oct; 27(10):1806-1817. PubMed ID: 34621053
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.
    Mądry K; Lis K; Tukiendorf A; Szwedyk P; Kapelko-Słowik K; Subocz E; Gołos A; Makowska W; Masternak A; Kopińska A; Czemerska M; Zawadzka-Leska S; Rusicka P; Drozd-Sokołowska J; Wiater E; Hołojda J; Pogłódek B; Centkowski P; Waszczuk-Gajda A; Machowicz R; Hałka J; Czerw T; Basak G; Dwilewicz-Trojaczek J
    Hematology; 2021 Dec; 26(1):556-564. PubMed ID: 34384334
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. LOC101928834, a novel lncRNA in Wnt/β-catenin signaling pathway, promotes cell proliferation and predicts poor clinical outcome in myelodysplastic syndromes.
    Li N; Ma Y; Wang W; Yin CC; Wu W; Sun R; Zhao G; Li S; Wang X
    Clin Sci (Lond); 2020 Jun; 134(11):1279-1293. PubMed ID: 32463458
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases.
    Wu B; Ingersoll K; Jug R; Yang LH; Luedke C; Lo A; Su P; Liu X; Rehder C; Gong J; Lu CM; Wang E
    Am J Clin Pathol; 2017 Dec; 149(1):55-66. PubMed ID: 29228125
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
    Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
    Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
    van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
    Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Research on molecular markers for epigenetic changes in myeloid malignancies].
    Li L; Sun XM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
    Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Verma A; McDonald EJ; Killick S; Hellström-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
    J Clin Oncol; 2013 Oct; 31(28):3557-64. PubMed ID: 24002510
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
    Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
    J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
    Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes.
    Cheng CL; Hou HA; Jhuang JY; Lin CW; Chen CY; Tang JL; Chou WC; Tseng MH; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Br J Cancer; 2011 Sep; 105(7):975-82. PubMed ID: 21878936
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.